InvivoGen

InvivoGen is a long-established, privately-held provider of specialized research tools and reagents, with a core focus on immunology and infectious disease research. The company operates a B2B business model, generating revenue by supplying a comprehensive catalog of products including PRR ligands, inhibitors, antibodies, cell lines, and custom services to the global scientific community. Its strategic positioning leverages deep expertise in innate immunity pathways, which are critical for advancing research in immunotherapy, vaccine development, and inflammatory diseases. While not a therapeutic developer itself, InvivoGen is an essential enabler for drug discovery and basic research pipelines worldwide.

Integrated ecosystem of research tools for innate immunity and cell biology, including PRR ligands/inhibitors, engineered reporter cell lines, specialized vectors (CpG-free), biosimilar antibodies, and detection kits for pathways like TLR, NLR, RLR, cGAS-STING, and inflammasome signaling.

InvivoGen competes in the life science reagents market against giants like Thermo Fisher, Merck Millipore, and Abcam, as well as niche immunology-focused players. Its competitive advantage is deep specialization, curated product integration for innate immunity pathways, and a reputation as a specialist source for high-quality, hard-to-find reagents in this field.